logo-loader

Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion

Last updated: 10:23 23 Sep 2021 EDT, First published: 10:07 23 Sep 2021 EDT

Co-Diagnostics - Co-Diagnostics Inc. announces corporate rebranding after period of transformative growth and expansion
Co-Diagnostics is developing an at-home and point-of-care PCR testing platform aimed at providing inexpensive, fast and accurate test results in residences, schools, physicians, and dental offices, businesses, cruise ships, hotels, and other settings worldwide

Co-Diagnostics (NASDAQ:CODX) Inc. is rebranding its image to better reflect its growing scope, mission, and upcoming expansion into new diagnostics verticals.

Its Logix Smart COVID-19 Test was the first test developed and manufactured by a US-based company to obtain regulatory clearance to be sold as an in vitro diagnostic (IVD) for the diagnosis of SARS-CoV-2 (COVID-19) in markets that accept the CE-marking as valid regulatory approval.

Since then, the company has sold over 22 million tests to hundreds of labs in over 50 countries and throughout the US. 

READ: Co-Diagnostics says its Logix Smart ABC Test is authorized for use in Mexico

As a result of further important innovation, research and development, Co-Diagnostics (NASDAQ:CODX) said it is developing an at-home and point-of-care PCR testing platform aimed at providing inexpensive, fast and accurate test results in residences, schools, physicians, and dental offices, businesses, cruise ships, hotels, and other settings worldwide. 

The extraction-free platform will utilize patient saliva samples that are placed in a small, reusable PCR instrument with results available on a smartphone in less than 30 minutes, sample to result.

In anticipation of the introduction of this new and groundbreaking diagnostic platform, the company said it is rebranding its image to better reflect its expanded scope, mission, and upcoming expansion into new diagnostics verticals, in addition to ongoing development in liquid biopsy for mutations associated with cancer, and agricultural applications.

The rebranding, which includes a new logo, website, and other related visual assets and marketing materials will take place over the next several months as additional optimization, validation, and clinical studies for the new device are completed prior to submission for FDA EUA regulatory review.

“Our mission and opportunity to provide broad, affordable access to best-in-class, potentially life-saving diagnostic products for patients around the world is reflected in our new products, test menu expansion, and especially with our forthcoming at home and point-of-care platform,” said CEO Dwight Egan in a statement.

“The new logo was inspired by the endless possibilities inherent in each strand of DNA and reflects the inclusivity and democratization of gold standard PCR testing for a wide array of infectious diseases worldwide.”

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Co-Diagnostics to reach wider audience with FDA Emergency Use Authorization...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the molecular diagnostics company's Logix Smart coronavirus test has obtained Emergency Use Authorization from the FDA to be used to diagnose SARS-CoV-2. Egan says the authorization confirms the quality and performance of the...

on 04/07/2020